Myomo (MYO) Stock Price, News & Analysis

Company Overview

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $2.02 to $2.14
• 50-Day Range: $1.95 to $3.42
• 52-Week Range: $1.85 to $7.17
• Volume: 246,960 shs
• Average Volume: 518,756 shs
• Market Capitalization: $72.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.67
• Consensus Rating: Buy

Myomo Stock Analysis - MarketRank™

Myomo scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Myomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Myomo has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Myomo are expected to grow in the coming year, from ($0.18) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Myomo is -13.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Myomo is -13.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Myomo has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.96% of the float of Myomo has been sold short.

Short Interest Ratio / Days to Cover

Myomo has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myomo has recently increased by 57.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Myomo does not currently pay a dividend.

Dividend Growth

Myomo does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.96% of the float of Myomo has been sold short.

Short Interest Ratio / Days to Cover

Myomo has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myomo has recently increased by 57.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

Myomo has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.08 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Myomo this week, compared to 2 articles on an average week.

Search Interest

Only 7 people have searched for MYO on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

4 people have added Myomo to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Myomo insiders have bought more of their company's stock than they have sold. Specifically, they have bought $390,093.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.54% of the stock of Myomo is held by insiders.

Percentage Held by Institutions

44.99% of the stock of Myomo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MYO Stock Analysis - Frequently Asked Questions

How have MYO shares performed this year?

Myomo's stock was trading at $6.03 at the start of the year. Since then, MYO shares have decreased by 66.5% and is now trading at $2.02.

How were Myomo's earnings last quarter?

Myomo, Inc. (NYSEAMERICAN:MYO) posted its earnings results on Wednesday, November, 6th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The business earned $9.21 million during the quarter, compared to the consensus estimate of $7.95 million. Myomo had a negative net margin of 15.05% and a negative trailing twelve-month return on equity of 35.57%.
Read the conference call transcript.

Who are Myomo's major shareholders?

Myomo's top institutional investors include Summit Financial Strategies Inc. (0.04%). Insiders that own company stock include Paul R Gudonis, David A Henry, Thomas F Kirk, Micah Mitchell, Harry Kovelman, Milton Mayo Morris and Thomas Aloysius Jr Crowley.
View institutional ownership trends.

How do I buy shares of Myomo?

Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Myomo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Myomo investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 7/28/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:MYO
• CIK: 1369290
• Web: myomo.com
• Phone: (617) 996-9058
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Myomo: $9.67
• High Price Target: $11.50
• Low Price Target: $8.00
• Potential Upside/Downside: +372.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.18 million
• Net Margins: -15.05%
• Pretax Margin: -13.96%
• Return on Equity: -35.57%
• Return on Assets: -20.11%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.37

Sales & Book Value

• Annual Sales: $32.55 million
• Price / Sales: 2.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.82 per share
• Price / Book: 2.49

Miscellaneous

• Outstanding Shares: 35,980,000
• Free Float: 34,346,000
• Market Cap: $73.58 million
• Optionable: Not Optionable
• Beta: 1.39